Vincenzo Maria Perriello

Vincenzo Maria Perriello


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
VPVincenzo Maria Perriello
Vincenzo Maria Perriello
MRMaria Caterina Rotiroti
Maria Caterina Rotiroti
IPIlaria Pisani
Ilaria Pisani
SGStefania Galimberti
Stefania Galimberti
GAGaia Alberti
Gaia Alberti
STSarah Tettamanti
Sarah Tettamanti
Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells demonstrated a high therapeutic potential, but further development is required to ensure a safe and durable disease remission in AML, especially in elderly patients. To date, translation of CAR T-cell therapy in AML is limited by the absence of an ideal tumor-specific antigen. CD123 and CD33 are the 2 most widely overexpressed leukemic stem cell biomarkers but their shared expression with endothelial and hematopoietic stem and progenitor cells increases the risk of undesired vascular and hematologic toxicities. To counteract this issue, we established a balanced dual-CAR strategy aimed at reducing off-target toxicities while retaining full functionality against AML. Cytokine-induced killer (CIK) cells, coexpressing a first-generation low affinity anti-CD123 interleukin-3–zetakine (IL-3z) and an anti-CD33 as costimulatory receptor without activation signaling domains (CD33.CCR), demonstrated a powerful antitumor efficacy against AML targets without any relevant toxicity on hematopoietic stem and progenitor cells and endothelial cells. The proposed optimized dual-CAR cytokine-induced killer cell strategy could offer the opportunity to unleash the potential of specifically targeting CD123+/CD33+ leukemic cells while minimizing toxicity against healthy cells.

14 April 2016 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
OEon behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)
on behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)
RPRoberta Della Pepa
Roberta Della Pepa
Marco PicardiMarco Picardi
Marco Picardi
FSFedarica Sora
Fedarica Sora
MSM. Stamouli
M. Stamouli
Livio PaganoLivio Pagano
Livio Pagano
Purpose Chronic disseminated candidiasis (CDC) is a complication of Candida infection in immunocompromised patients, involving the liver and spleen, and rarely other organs. The aim of the study is to identify the best antifungal drug for hematologic immunocompromised patients with CDC. Methods In this multicentric retrospective study, the charts of 20 patients with CDC following cytotoxic agent protocols for hematological malignancies, diagnosed from 2003 to 2013, were analyzed. The response to systemic antifungal therapy within 90 days from CDC diagnosis and the possible delay in chemotherapy plan, due to the infection, were evaluated. Results Six patients were treated with high-dose (HD; 5 mg/kg/daily) liposomal amphotericin B (L-AmB), whereas three received standard-dose (SD) L-AmB (3 mg/kg/daily). Azoles were given to six patients; the remaining five were treated with echinocandins. All patients treated with HD L-AmB (6/6—100 %) achieved complete resolution of CDC; one of them had to interrupt the chemotherapy program for the infection. In the SD L-AmB group, treatment failed in the 100 % of cases and one patient had to delay chemotherapy for the infection. Of the six patients who received azoles, two achieved complete resolution of the infection, four experienced treatment failure, and only three performed chemotherapy as planned. Echinocandins treatment resulted in complete resolution of the infection in 2/5 cases, partial response in 2/5 cases, and failure in one case. In this group, 3/5 patients completed chemotherapy as planned. Conclusions This study shows that HD L-AmB was particularly effective against CDC in hematologic patients, allowing most patients to continue cytotoxic agent program.

14 March 2023 in British Journal of Haematology
Verified
Journal Article
Open access
Arnon NaglerArnon Nagler
Arnon Nagler
VPVincenzo Maria Perriello
Vincenzo Maria Perriello
LFLorenza Falini
Lorenza Falini
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini
Summary: Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage immunotherapy for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), offering ~40% of long‐term responses. In everyday clinical practice, haematologists involved in CAR T cell treatment of patients with R/R DLBCL have to deal with diagnostically complex cases and difficult therapeutic choices. The availability of novel immunotherapeutic agents for R/R DLBCL and recent advances in understanding CAR T‐cell failure mechanisms demand a rational approach to identify the best choice for bridging therapy and managing post‐CAR T‐cell therapy relapses. Moreover, positron emission tomography/computerised tomography may result in false‐positive interpretation, highlighting the importance of post‐treatment biopsy. In this review, we discuss all above issues, presenting four instructive cases, with the aim to provide criteria and new perspectives for CAR T‐cell treatment of DLBCL.

22 June 2024 in American Journal of Hematology
Verified
Journal Article
Open access
AVAlessandra Venanzi
Alessandra Venanzi
VCValeria Cardinali
Valeria Cardinali
VPVincenzo Maria Perriello
Vincenzo Maria Perriello
Francesco AlbanoFrancesco Albano
Francesco Albano
GCGaetano Cimino
Gaetano Cimino
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini

8 November 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
VPVincenzo Maria Perriello
Vincenzo Maria Perriello
LFLorenza Falini
Lorenza Falini
LRLoredana Ruggeri
Loredana Ruggeri
AIAlessandra Innocente
Alessandra Innocente
SBStelvio Ballanti
Stelvio Ballanti
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini

13 September 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
AVAlessandra Venanzi
Alessandra Venanzi
ASAlessia Santi
Alessia Santi
RZRenato Zambello
Renato Zambello
CGClaudia Giordano
Claudia Giordano
APAlessandra Pucciarini
Alessandra Pucciarini
ETEnrico Tiacci
Enrico Tiacci